• Amygdalus communis vas
• Diabetes mellitus
• Glycated hemoglobin
• Lichen planus
• Mendelian randomization analysis
• Oral
• Quercetin
• Thalidomide

• Humans
• Lichen Planus, Oral/genetics
• Lichen Planus, Oral/drug therapy
• Glycated Hemoglobin/analysis
• Diabetes Mellitus, Type 2/genetics
• Diabetes Mellitus, Type 2/complications
• Diabetes Mellitus, Type 2/drug therapy
• Diabetes Mellitus, Type 1/genetics
• Diabetes Mellitus, Type 1/complications
• Diabetes Mellitus, Type 1/drug therapy
• Mendelian Randomization Analysis
• Blood Glucose/analysis
• Drugs, Chinese Herbal/therapeutic use
• Hypoglycemic Agents/therapeutic use

• Lichen Planus
• Mouth Neoplasms
• Mucositis
• Oral Ulcer
• Platelet-Rich Fibrin
• Regeneration

• Platelet-Rich Fibrin
• Humans
• Mouth Mucosa/pathology
• Wound Healing/drug effects
• Mouth Diseases/drug therapy
• Animals

• Otolaryngology
• Platelet-rich fibrin
• Platelet-rich plasma
• Regeneration
• Systematic review
• Wound healing

• Humans
• Otolaryngology/methods
• Otorhinolaryngologic Diseases/therapy
• Platelet-Rich Fibrin
• Platelet-Rich Plasma

• corticosteroids
• meta-analysis
• oral lichen planus
• prf
• prp

• Lichen planus, oral
• Platelet-rich fibrin
• Platelet-rich plasma

• Lichen Planus, Oral/drug therapy
• Humans
• Platelet-Rich Plasma
• Platelet-Rich Fibrin
• Administration, Topical
• Adrenal Cortex Hormones/therapeutic use
• Adrenal Cortex Hormones/administration & dosage

• cardiac surgery
• drainage
• platelet-rich plasma
• surgical site infection (SSI)

• Humans
• Surgical Wound Infection/prevention & control
• Surgical Wound Infection/epidemiology
• Platelet-Rich Plasma
• Cardiac Surgical Procedures/adverse effects
• Drainage
• Randomized Controlled Trials as Topic

• 82172060 Natural Science Foundation of China
• Natural Science Foundation of China

• Oral lesions
• Oral ulcers
• Platelet concentrates
• Platelet-rich fibrin
• Platelet-rich plasma

• erosive type
• microbes
• nonpharmacological treatment
• oral lichen planus
• pharmacological treatment

• Humans
• Lichen Planus, Oral/drug therapy
• Lichen Planus, Oral/pathology
• Cell Transformation, Neoplastic

• L‐PRF
• horizontal centrifugation
• platelet‐rich fibrin
• tissue regeneration
• wound healing

• Humans
• Platelet-Rich Fibrin
• Injections

• Biomaterials
• Dental implant
• Drug delivery
• Nanomaterials

• Humans
• Anodontia
• Biocompatible Materials
• Dental Implants
• Drug Delivery Systems
• Inflammation

• i-prf
• injectable platelet-rich fibrin
• lesion size
• oral lichen planus
• pain assessment

• Bio-materials
• growth factor
• oral disease
• platelet-rich fibrin

• Humans
• Platelet-Rich Fibrin/chemistry
• Dentistry
• Biocompatible Materials/chemistry
• Regenerative Medicine

• Alveolar bone regeneration
• Osteogenesis
• Platelet-rich fibrin
• Scaffold
• Signaling pathways

• Platelet-Rich Fibrin
• Phosphatidylinositol 3-Kinases
• Bone Regeneration
• Osteogenesis

• Oral lichen planus
• Platelet concentrates
• Steroid
• Topical treatment

• Humans
• Lichen Planus, Oral/drug therapy
• Palliative Care
• Pain
• Pain Management
• Adrenal Cortex Hormones/therapeutic use

• Alveolar ridge preservation
• Bone healing
• Histomorphometry
• Implant treatment
• Platelet concentrates
• Platelet-rich fibrin
• Platelet-rich plasma

• Humans
• Tooth Socket
• Alveolar Process
• Osteogenesis
• Tooth
• Platelet-Rich Plasma
• Tooth Extraction
• Fibrin
• Alveolar Ridge Augmentation

• Universidad Complutense de Madrid

• Antibiotics
• Antimicrobial activity
• Antimicrobial resistance
• Drug delivery
• Oral surgery
• Platelet-rich fibrin

• MARF
• PRF
• attached gingiva

• Male
• Female
• Humans
• Young Adult
• Adult
• Middle Aged
• Platelet-Rich Fibrin
• Gingiva/surgery
• Gingival Recession/surgery
• Face
• Pain, Postoperative/etiology
• Pain, Postoperative/prevention & control

• Vice Chancellor for Research and Technology, Hamadan University of Medical Sciences

• Biomaterial
• I-PRF
• Platelet-rich Fibrin
• Regenerative Dentistry
• Tissue Regeneration

• R15 DE027533 NIDCR NIH HHS
• R56 DE029191 NIDCR NIH HHS

Collagen membrane and platelet-rich fibrin (PRF) have emerged as vital biomaterials in the field of periodontal regeneration. Minimally invasive techniques are being preferred by most periodontists, as it is patient compliant with fewer post-surgical complications as compared to conventional surgical techniques. Thus, in this study we have evaluated the effect of injectable PRF (i-PRF) with collagen membrane compared with collagen membrane alone using vestibular incision subperiosteal tunnel access (VISTA) technique for gingival recession coverage.

To compare the efficacy of VISTA using collagen membrane with collagen membrane soaked in injectable PRF for gingival recession coverage.

A split mouth randomized controlled clinical trial was designed;13 subjects having at least 2 teeth indicated for recession coverage were enrolled in this study. The sites were randomly assigned to control group (VISTA using collagen membrane alone) and the test group (VISTA using collagen membrane with i-PRF). The clinical parameters assessed were pocket depth, recession depth (RD), recession width (RW), relative attachment level, keratinised tissue width (KTW), keratinised tissue thickness (KTT), and percentage root coverage.

RD showed a statistically significant difference between the test group at 3 mo (0.5 ± 0.513) and 6 mo (0.9 ± 0.641) and the control group at 3 mo (0.95 ± 0.51) and 6 mo (1.5 ± 0.571), with P values of 0.008 and 0.04, respectively. RW also showed a statistically significant difference between the test group at 3 mo (1 ± 1.026) and 6 mo (1.65 ± 1.04) and the control group at 3 mo (1.85 ± 0.875) and 6 mo (2.25 ± 0.759), with P values of 0.008 and 0.001, respectively. Results for KTW showed statistically significant results between the test group at 1 mo (2.85 ± 0.489), 3 mo (3.5 ± 0.513), and 6 mo (3.4 ± 0.598) and the control group at 1 mo (2.45 ± 0.605), 3 mo (2.9 ± 0.447), and 6 mo (2.75 ± 0.444), with P values of 0.04, 0.004, and 0.003, respectively. Results for KTT also showed statistically significant results between test group at 1 mo (2.69 ± 0.233), 3 mo (2.53 ± 0.212), and 6 mo (2.46 ± 0.252) and the control group at 1 mo (2.12 ± 0.193), 3 mo (2.02 ± 0.18), and 6 mo (1.91 ± 0.166), with P values of 0.001, 0.001, and 0.001, respectively. The test group showed 91.6%, 81.6%, and 67% root coverage at 1 mo, 3 mo, and 6 mo, while the control group showed 82.3%, 66.4%, and 53.95% of root coverage at 1 mo, 3 mo, and 6 mo, respectively.

The use of minimally invasive VISTA technique along with collagen membrane and injectable form of platelet-rich fibrin can be successfully used as a treatment method for multiple or isolated gingival recessions of Miller’s class-I and class-II defects.

• Vestibular incision subperiosteal tunnel access
• Injectable platelet-rich fibrin
• Collagen membrane
• Gingival recessions
• Treatment

• Intralesional injection
• Lichen planus
• Platelet-rich fibrin
• Triamcinolone acetonide

Adrenal glands are the major source of glucocorticoids, but recent studies indicate tissue-specific production of cortisol, including that in the oral mucosa. Both endogenous and exogenous glucocorticoids regulate the production of several proteins, including the glucocorticoid-induced leucine zipper (GILZ) and Annexin A1, which play important roles in the regulation of immune and inflammatory responses. Common inflammation-associated oral conditions include lichen planus and candidiasis, but the status of GILZ and Annexin A1 in these human conditions remains to be established. Accordingly, archived paraffin-embedded biopsy samples were subjected to immunohistochemistry to establish tissue localization and profile of GILZ and Annexin A1 coupled with the use of hematoxylin–eosin stain for histopathological assessment; for comparison, fibroma specimens served as controls. Histopathological examination confirmed the presence of spores and pseudohyphae for oral candidiasis (OC) specimens and marked inflammatory cell infiltrates for both OC and oral lichen planus (OLP) specimens compared to control specimens. All specimens displayed consistent and prominent nuclear staining for GILZ throughout the full thickness of the epithelium and, to varying extent, for inflammatory infiltrates and stromal cells. On the other hand, a heterogeneous pattern of nuclear, cytoplasmic, and cell membrane staining was observed for Annexin A1 for all specimens in the suprabasal layers of epithelium and, to varying extent, for inflammatory and stromal cells. Semi-quantitative analyses indicated generally similar fractional areas of staining for both GILZ and Annexin A1 among the groups, but normalized staining for GILZ, but not Annexin A1, was reduced for OC and OLP compared to the control specimens. Thus, while the cellular expression pattern of GILZ and Annexin A1 does not differentiate among these conditions, differential cellular profiles for GILZ vs. Annexin A1 are suggestive of their distinct physiological functions in the oral mucosa.

• Annexin A1
• GILZ
• human
• immunohistochemistry
• oral candidiasis
• oral lichen planus

• Annexin A1/metabolism
• Candidiasis, Oral/immunology
• Candidiasis, Oral/pathology
• Humans
• Lichen Planus, Oral/immunology
• Lichen Planus, Oral/pathology
• Transcription Factors/metabolism

To evaluate the clinical efficacy of intralesional platelet‐rich plasma (PRP) injections compared to intralesional triamcinolone acetonide (TA) injections in the treatment of erosive oral lichen planus (EOLP).

Twenty patients with EOLP were assigned randomly to either PRP or TA group. Patients received weekly intralesional injections for 4 weeks, and then followed up for 3 months on regular visits every 2 weeks. Pain scores using numerical pain score and clinical score were recorded by a blinded assessor each visit for all patients and remission score at the end of the trial was recorded.

Both groups showed significant improvement in the clinical parameters (pain and clinical score) “p = .001.” Regarding remission of the lesions, 80% of patients in the PRP group showed complete remission compared to 70% in the TA group. However, there is no statistical significance when comparing the two groups in pain score, clinical score, or remission.

PRP injections could be considered as an effective alternative single treatment modality for EOLP. The protocol for this study registered in Clinicaltrials.gov registry under the identifier number: NCT03293368.

• intralesional injections
• oral lichen planus
• platelet rich plasma

• Humans
• Injections, Intralesional
• Lichen Planus, Oral/drug therapy
• Lichen Planus, Oral/pathology
• Pain/drug therapy
• Pilot Projects
• Platelet-Rich Plasma
• Triamcinolone Acetonide

As a source of growth factors for expediting wound healing and tissue regeneration, plasma-rich plasma (PRP) has been extensively applied in diverse fields including orthopaedics, ophthalmology, oral and maxillofacial surgery, dentistry, and gynaecology. However, the function of PRP in metabolic regulations remains enigmatic. A standardized method was devised herein to enrich growth factors and to lyophilize it as enhanced PRP (ePRP) powder, which could become ubiquitously available without mechanical centrifugation in clinical practice. To identify metabolic reprogramming in human dermal fibroblasts under ePRP treatment, putative metabolic targets were identified by transcriptome profiling and validated for their metabolic effects and mechanism. ePRP does not only promote wound healing but re-aligns energy metabolism by shifting to glycolysis through stimulation of glycolytic enzyme activity in fibroblasts. On the contrary, oxygen consumption rates and several mitochondrial respiration activities were attenuated in ePRP-treated fibroblasts. Furthermore, ePRP treatment drives the mitochondrial resetting by hindering the mitochondrial biogenesis-related genes and results in a dampened mitochondrial mass. Antioxidant production was further increased by ePRP treatment to prevent reactive oxygen species formation. Besides, ePRP also halts the senescence progression of fibroblasts by activating SIRT1 expression. Importantly, the glycolytic inhibitor 2-DG can completely reverse the ePRP-enhanced wound healing capacity, whereas the mitochondrial inhibitor oligomycin cannot. This is the first study to utilize PRP for comprehensively investigating its effects on the metabolic reprogramming of fibroblasts. These findings indicate that PRP’s primary metabolic regulation is to promote metabolic reprogramming toward glycolytic energy metabolism in fibroblasts, preserving redox equilibrium and allowing anabolic pathways necessary for the healing and anti-ageing process.

• ageing
• glycolysis
• metabolic reprogramming
• platelet-rich plasma
• regenerative medicine

• Cell Culture Techniques
• Cell Line
• Cell Proliferation
• Fibroblasts/cytology
• Fibroblasts/metabolism
• Glycolysis
• Humans
• Platelet-Rich Plasma/metabolism
• Regenerative Medicine
• Sirtuin 1/metabolism
• Skin/cytology
• Skin/metabolism
• Wound Healing

• autologous growth factors
• carrier systems
• drug delivery
• endogenous growth factors
• platelet concentrates
• platelet-rich fibrin
• tissue engineering

• Blood Platelets/metabolism
• Humans
• Intercellular Signaling Peptides and Proteins/metabolism
• Platelet-Rich Fibrin/metabolism
• Platelet-Rich Plasma/metabolism
• Regenerative Medicine/methods

• lzp-2020/1-0054 Latvian Council of Science

Our study compared the effects of injectable platelet-rich fibrin (i-PRF) with those of corticosteroids in the treatment of erosive oral lichen planus (EOLP).

This split-mouth study included 24 individuals diagnosed histopathologically with bilateral EOLP. One bilateral lesion was injected with i-PRF, whereas the other was injected with methylprednisolone acetate in four sessions at 15-day intervals. Visual analog scale (VAS) for pain and satisfaction, oral health impact profile scale-14, and the lesion size were used.

The intragroup comparisons showed a significant decrease in VAS-pain and lesion size in both the i-PRF group (from 81.88±17.74 to 13.33±18.34, and from 4.79±0.41 to 1.88±1.08, respectively) and the corticosteroid group (from 80.21±17.35 to 23.33±26.81, and from 4.71±0.46 to 2.21±1.35, respectively) in the 6th month compared to baseline (p<0.001). Moreover, VAS-satisfaction increased significantly in both the i-PRF group (from 26.67±17.8 to 85.63±16.24) and the corticosteroid group (from 28.33±17.05 to 74.38±24.11) in the 6th month compared to baseline (p<0.001). However, no significant difference in any value occurred in the intergroup comparisons.

In patients with EOLP, both methods decreased pain and lesion size similarly, and both increased satisfaction. Therefore, the use of i-PRF may be considered an option in cases refractory to topical corticosteroid therapy. Biochemical and histopathological studies are required to reveal the mechanism of i-PRF action in EOLP treatment.

Blood derivates, such as platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), are autogenous sources of many growth factors that are involved in the healing and regeneration of tissues, and for this reason, are used in dentistry treatments. This fact also contributes to the growing interest in these biomaterials in regenerative personalized medicine. The multitude of platelet-rich forms creates many possibilities for their use. This semi-systematic review describes and compares the methods of obtaining properties and potential uses of these materials in personalized treatments.

• guided tissue regeneration
• periodontitis
• platelet-rich fibrin
• platelet-rich plasma
• regenerative endodontics

Background: oral lichen planus (OLP) is a mucocutaneous disease that affects about 4% of the global population. Hepatitis C virus (HCV) was linked to lichen planus. The current study aimed to assess the impact of OLP associated or not with HCV infection on the oral health-related quality of life (OHRQoL). Methods: The study included patients diagnosed with OLP who filled in the Romanian version of OHIP-14 questionnaire at their first appointment and 6 months later, after the OLP treatment. A control group of OLP-free subjects similar as age and sex was also included in the study. Results: 68 patients with OLP and 46 controls were included in the study. The OHIP scores are significantly higher on OLP group than controls (p-value < 0.0001) and significantly reduced at 6-month follow-up (p-values: < 0.0001 pre- vs. post-treatment in OLP group). Patients with and without HCV associated with OLP demonstrated a similar oral quality of life (p-values > 0.05). Conclusions: the OHRQoL for patients suffering from OLP is compromised but is improved after treatment. The HCV associated with OLP did not influence the overall OHRQoL, but the patients who associate HCV reported more frequently aching in the mouth and discomfort eating food at six-month follow-up.

• OHIP-14 questionnaire
• hepatitis C virus
• oral lichen planus
• quality of life (QoL)

• ALG, alginate
• BZ, border zone
• Drug delivery
• HA, hyaluronic acid
• IZ, infarcted zone
• Injectable hydrogel
• LVEDd, left ventricular end-diastolic diameter
• LVEF, left ventricular ejection fractions
• LVESd, left ventricular end-systolic diameter
• LVFS, left ventricular fractional shortening
• Ly-PRF, lyophilized platelet-rich fibrin
• Lyophilized platelet-rich fibrin
• MI, myocardial infarction
• Myocardial infarction
• PET-CT, positron emission tomography-computerized tomography
• PRF, platelet-rich fibrin
• PRP, platelet rich plasma
• SUV, standardized uptake value
• TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling
• Vascularization
• iNOS, inducible nitric oxide synthase

• chronic inflammatory oral disease
• laser therapy
• lichen planus
• low-level laser therapy
• oral laser applications
• photobiomodulation

• immediate implants
• marginal bone loss
• platelet concentrates
• platelet-rich fibrin
• platelet-rich plasma

Autologous platelet-rich fibrin (PRF) is derived from the blood and its use in the bone tissue engineering has emerged as an effective strategy for novel drug and growth factor delivery systems. Studies have approved that combined therapy with PRF ensures higher biological outcomes, but patients still undergo additional treatment with antibiotic drugs before, during, and even after the implantation of biomaterials with PRF. These systematically used drugs spread throughout the blood and lead not only to positive effects but may also induce adverse side effects on healthy tissues. Vancomycin hydrochloride (VANKA) is used to treat severe Staphylococcal infections but its absorption in the target tissue after oral administration is low; therefore, in this study, we have developed and analyzed two kinds of VANKA carriers—liposomes and microparticles in 3D PRF matrices. The adjustment, characterization, and analysis of VANKA carriers in 3D PRF scaffolds is carried out in terms of encapsulation efficiency, drug release kinetics and antibacterial activity; furthermore, we have studied the micro- and macrostructure of the scaffolds with microtomography.

• PLGA
• drug delivery
• drug release
• liposomes
• microcapsules
• microtomography
• phospholipids
• platelet-rich fibrin
• vancomycin

The clinical application of human platelet lysate (HPL) holds promise for tissue regeneration, and the development of an efficient vehicle for its delivery is desired. Chitosan-based hydrogels are potential candidates, but they often exhibit weak mechanical properties. In this study, a chitosan/gelatin (CS-GE) hydrogel crosslinked by glyoxal was fabricated for sustained release of HPL. The influence of HPL on Hs68 fibroblast and human umbilical vein endothelial cell (HUVEC) culture was evaluated, and we found that supplementing 5% HPL in the medium could significantly improve cell proliferation relative to supplementing 10% fetal bovine serum (FBS). Moreover, HPL accelerated the in vitro wound closure of Hs68 cells and facilitated the tube formation of HUVECs. Subsequently, we fabricated CS-GE hydrogels crosslinked with different concentrations of glyoxal, and the release pattern of FITC-dextrans (4, 40 and 500 kDa) from the hydrogels was assessed. After an ideal glyoxal concentration was determined, we further characterized the crosslinked CS-GE hydrogels encapsulated with different amounts of HPL. The HPL-incorporated hydrogel was shown to significantly promote the proliferation of Hs68 cells and the migration of HUVECs. Moreover, the release pattern of transforming growth factor-β1 (TGF-β1) and platelet-derived growth factor-BB (PDGF-BB) from hydrogel was examined in vitro, demonstrating a sustained release profile of the growth factors. Finally, the chick chorioallantoic membrane assay revealed that HPL encapsulation in the hydrogel significantly stimulated angiogenesis in ovo. These results demonstrate the great potential of the crosslinked CS-GE hydrogel to serve as an effective delivery system for HPL to promote tissue regeneration.

• angiogenesis
• chitosan
• gelatin
• glyoxal
• human platelet lysate
• hydrogel
• tissue regeneration

To develop cost-effective and efficient bone substitutes for improved regeneration of bone defects, heparin-modified mineralized collagen scaffolds were functionalized with concentrated, naturally occurring bioactive factor mixtures derived from adipose tissue, platelet-rich plasma and conditioned medium from a hypoxia-treated human bone marrow-derived mesenchymal stem cell line. Besides the analysis of the release kinetics of functionalized scaffolds, the bioactivity of the released bioactive factors was tested with regard to chemotaxis and angiogenic tube formation. Additionally, functionalized scaffolds were seeded with human bone marrow-derived mesenchymal stromal cells (hBM-MSC) and their osteogenic and angiogenic potential was investigated. The release of bioactive factors from the scaffolds was highest within the first 3 days. Bioactivity of the released factors could be confirmed for all bioactive factor mixtures by successful chemoattraction of hBM-MSC in a transwell assay as well as by the formation of prevascular structures in a 2D co-culture system of hBM-MSC and human umbilical vein endothelial cells. The cells seeded directly onto the functionalized scaffolds were able to express osteogenic markers and form tubular networks. In conclusion, heparin-modified mineralized collagen scaffolds could be successfully functionalized with naturally occurring bioactive factor mixtures promoting cell migration and vascularization.

• MSC secretome
• adipose tissue extract
• bone regeneration
• bone substitute materials
• collagen scaffold
• growth factor
• hypoxia-conditioned medium
• platelet lysates

The purpose of this work is to describe the use of Fibrin-Plasma Rich in Growth Factors (PRGF) membranes for the treatment of a rabbit alkali-burn lesion. For this purpose, an alkali-burn lesion was induced in 15 rabbits. A week later, clinical events were evaluated and rabbits were divided into five treatment groups: rabbits treated with medical treatment, with a fibrin-PRGF membrane cultured with autologous or heterologous rabbit Limbal Epithelial Progenitor Cells (LEPCs), with a fibrin-PRGF membrane in a Simple Limbal Epithelial Transplantation and with a fibrin-PRGF membrane without cultured LEPCs. After 40 days of follow-up, corneas were subjected to histochemical examination and immunostaining against corneal or conjunctival markers. Seven days after alkali-burn lesion, it was observed that rabbits showed opaque cornea, new blood vessels across the limbus penetrating the cornea and epithelial defects. At the end of the follow-up period, an improvement of the clinical parameters analyzed was observed in transplanted rabbits. However, only rabbits transplanted with cultured LEPCs were positive for corneal markers. Otherwise, rabbits in the other three groups showed positive staining against conjunctival markers. In conclusion, fibrin-PRGF membrane improved the chemically induced lesions. Nonetheless, only fibrin-PRGF membranes cultured with rabbit LEPCs were able to restore the corneal surface.

• PRP
• alkali-burn lesion
• fibrin-PRGF membrane
• in vitro expansion
• limbal stem cell

• Animals
• Autografts
• Burns, Chemical/metabolism
• Burns, Chemical/pathology
• Burns, Chemical/therapy
• Epithelial Cells/metabolism
• Epithelial Cells/pathology
• Epithelial Cells/transplantation
• Eye Burns/metabolism
• Eye Burns/pathology
• Eye Burns/therapy
• Fibrin/pharmacology
• Limbus Corneae/metabolism
• Limbus Corneae/pathology
• Plasma
• Rabbits
• Stem Cell Transplantation
• Stem Cells/metabolism
• Stem Cells/pathology

It was the aim of this study to histometrically evaluate guided tissue regeneration (bioresorbable membrane plus bone mineral) (GTR) with or without platelet-derived growth factor (PDGF) in two different types of class III furcation defects (small keyhole defects and horizonal defects) in monkeys. In six cynomolgus monkeys, two types of class III furcation defects were created and allowed to chronify for 5 months in mandibular first and second molars. After a hygiene program the molars were assigned to GTR group (collagen membrane plus bovine bone mineral), PDGF group (collagen membrane plus bovine bone mineral plus PDGF), or negative control group (flap reposition only). Histologic sections were made after 7 months of healing and descriptive statistics were provided from the histometric parameters. Postoperative healing was uneventful despite marginal membrane exposures in the GTR and PDGF group. Bone regeneration of 23–35% of the original defect area was found in the two treatment groups. In none of the evaluated key parameters (formation of bone, root cementum, connective tissue, or epithelium) differences were detected between GTR and PDGF groups. However, the negative control teeth exhibited better bone regeneration than the treatment groups. The type of class III defect did not influence the regenerative outcome. Within the limits of this study PDGF was not able to enhance the histologic regeneration of class III furcation areas in monkeys compared to bone mineral enhanced GTR treatment regardless of the defect configuration. Membrane exposure during early healing might have influenced these outcomes.

• animal study
• class III furcation
• guided tissue regeneration (GTR)
• histometric evaluation
• platelet-derived growth factor (PDGF)

• CGF
• PRF
• PRP
• autologous platelet concentrates
• facial rejuvenation
• periodontal regeneration

The aim of this study was to compare the microarchitecture of augmented bone following maxillary sinus augmentation (MSA) after healing periods of 3 (test) and 6 (control) months using the combination of advanced platelet-rich fibrin (A-PRF) and a serum albumin-coated bone allograft (SACBA). Twenty-six patients with 30 surgical sites who required two-stage MSA were enrolled and grafted with the combination of A-PRF and SACBAs. The surgical sites were randomly allocated to the test or control group. During implant site preparation, 17 bone core biopsy samples were collected from each study group for histological, histomorphometric and micromorphometric analysis. Resonance frequency analysis was performed at the time of implant placement and 6, 8, 10, and 12 weeks postoperatively. The percentage of newly formed bone was 44.89 ± 9.49% in the test group and 39.75 ± 8.15% in the control group (p = 0.100). The results of the µCT analysis showed no significant differences in morphometric parameters between the study groups. The implant stability quotient was not significantly different between the two groups at 10 and 12 weeks postoperatively. Based on these findings, the total treatment time may be reduced by 3 months with the use of A-PRF and SACBAs for two-stage MSA.

• allograft
• histomorphometry
• maxillary sinus augmentation
• micromorphometry
• platelet-rich fibrin
• resonance frequency analysis

• LSCC
• biologization
• blood concentrates
• bone-regeneration
• platelet-rich-fibrin
• regenerative therapy

• Biocompatible Materials/chemistry
• Cell Adhesion
• Cells, Cultured
• Centrifugation
• Culture Media/chemistry
• Culture Media/metabolism
• Cytokines/metabolism
• Humans
• Intercellular Signaling Peptides and Proteins/metabolism
• Osteoblasts/cytology
• Osteoblasts/physiology
• Platelet-Rich Fibrin
• Regeneration
• Tissue Scaffolds/chemistry